直接观察治疗与扩展年龄范围对季节性疟疾化学预防的影响:布基纳法索三组开放标签整群随机对照试验
该三组开放标签整群随机对照试验在布基纳法索Saponé开展,比较了项目化SMC与直接观察治疗(DOT)下SMC的效果,以及将SMC扩展至10岁以下儿童的影响。结果显示,5岁以下儿童中项目化SMC与DOT下SMC的寄生虫携带率无显著差异;将SMC扩展至5-9岁儿童可显著降低该年龄组的寄生虫携带率和临床疟疾发病率。
要点
- 5岁以下儿童中,DOT下SMC与项目化SMC的疟原虫携带率无显著差异。
- 将SMC扩展至5-9岁儿童可降低该年龄组疟原虫携带率和临床疟疾发病率。
- 基于血浆药物浓度的依从性评分高者临床疟疾发病率更低。
核心结论
- 5岁以下儿童中,项目化SMC与DOT下SMC的疟原虫携带率无显著差异。
- 将SMC扩展至5-9岁儿童可降低该年龄组的寄生虫携带和临床疟疾发病率。
- 研究结果支持将SMC年龄范围扩展至较大儿童,但需评估后勤和资金障碍。
研究设计与样本
- 三组、开放标签、整群随机对照试验,在布基纳法索Saponé开展。
- 共61个项目化SMC群组和62个(每个DOT组)由三个Compound组成的群组。
- 共纳入3467名所有年龄段参与者,其中980名为SMC目标个体。
- 儿童接受四轮磺胺多辛-乙胺嘧啶加阿莫地喹的SMC。
- 主要终点为传播季节结束时SMC目标年龄组的恶性疟原虫携带率。
临床怎么用
- 在5岁以下儿童中,项目化SMC与DOT下SMC效果相当,可继续项目化实施。
- 可考虑将SMC扩展至5-9岁儿童以降低该年龄组疟疾负担。
- 提高SMC依从性(如通过DOT)可能进一步降低临床疟疾发病率。
局限性
- 研究在布基纳法索单一地区开展,外推性需谨慎。
- 未采用正式缺失数据处理策略,使用改良意向性分析。
- 扩展SMC年龄范围的后勤和资金障碍需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Seasonal malaria chemoprevention (SMC) currently targets children younger than 5 years but can be extended to wider age ranges to reduce clinical burden in older populations. We aimed to evaluate the effect of programmatic SMC versus SMC via directly observed treatment (DOT) and the effect of extending SMC to children younger than 10 years on malaria clinical incidence, parasite carriage, and gametocyte carriage in individuals targeted and untargeted by SMC. METHODS: We conducted a three-group, open-label, cluster-randomised trial in Saponé (Burkina Faso) with three study groups: (1) programmatic SMC in children younger than 5 years; (2) SMC in children younger than 5 years with DOT (DOTu5); and (3) SMC in children younger than 10 years with DOT (DOTu10). The trial involved 61 programmatic SMC and 62 (each DOT group) clusters of three compounds. Eligible compounds had at least one child younger than 5 years and aged 5-9 years who had not participated in recent vaccine trials. Clusters were randomised (approximately 1:1:1) to the study groups by computer generation. Eligible children received four cycles of SMC with sulfadoxine-pyrimethamine and amodiaquine. The primary endpoint was Plasmodium falciparum parasite prevalence at the end of the transmission season in SMC-targeted age groups and compared between study groups. No formal missing data strategy was conducted; a modified intention-to-treat analysis was used based on those assessed during the endline survey. Secondary endpoints included drug plasma concentrations after the fourth cycle of SMC and incidence of clinical malaria during the entire malaria season. The trial is registered with ClinicalTrials.gov, NCT05878366, and is completed. FINDINGS: Between 13 July and 29 Aug 2023, 3467 participants of all ages were enrolled, including 980 SMC-targeted individuals (236 in the programmatic SMC group, 231 in the DOTu5 group, and 513 in the DOTu10 group). The parasite prevalence at the end of transmission season in children younger than 5 years was 24·9% (52 of 209 participants) in the programmatic SMC group compared with 19·7% (40 of 203 participants) in the DOTu5 group (rate ratio [RR] 0·84, 95% CI 0·55-1·30; p=0·4419). Parasite prevalence in children aged 5-9 years was lower in the DOTu10 group (28·1% [63 of 224 participants]) compared with the DOTu5 group (47·1% [98 of 208 participants]; RR 0·56, 95% CI 0·43-0·74; p<0·0001). The incidence of clinical malaria in children younger than 5 years was lower in the DOTu5 group compared with the programmatic SMC group (protective efficacy 0·57, 95% CI 0·29-0·74; p=0·0009) and lower in children aged 5-9 years in the DOTu10 group compared with the DOTu5 group (0·72, 0·54-0·83; p<0·001). Clinical incidence after the 4th cycle of SMC was also lower in individuals who were scored as adherent based on plasma drug concentrations compared with those who were scored as non-adherent (incidence rate ratio 0·21, 95% CI 0·09-0·51; 0·0006). INTERPRETATION: We observed no significant difference in parasite prevalence between programmatic SMC and SMC delivered through DOT in children younger than 5 years. Extending SMC to children aged 5-9 years reduced parasite carriage and incidence of clinical malaria in this age group. Although these findings support extending the SMC age range to older children, potential logistical and financial barriers need to be examined. FUNDING: Gates Foundation.
引用
- Yaro JB, Ouedraogo A, Moreno M, et al. Impact of directly observed treatment and extended age range of seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in Burkina Faso: a three-group, open-label, cluster-randomised, controlled trial. Lancet Infect Dis. 2026. PMID: 42526467. doi:10.1016/S1473-3099(26)00305-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。